Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?

J Rheumatol. 2013 Oct;40(10):1643-5. doi: 10.3899/jrheum.130875.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Juvenile / drug therapy*
  • Female
  • Humans
  • Infliximab
  • Male

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab